Home » Stocks » SURF

Surface Oncology, Inc. (SURF)

Stock Price: $6.07 USD -0.15 (-2.41%)
Updated Jul 29, 2021 4:00 PM EDT - Market closed
After-hours: $6.04 -0.03 (-0.49%) Jul 29, 7:46 PM
Market Cap 264.80M
Revenue (ttm) 89.20M
Net Income (ttm) 21.21M
Shares Out 41.62M
EPS (ttm) 0.53
PE Ratio 11.47
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 29
Last Price $6.07
Previous Close $6.22
Change ($) -0.15
Change (%) -2.41%
Day's Open 6.27
Day's Range 6.04 - 6.33
Day's Volume 473,421
52-Week Range 4.87 - 14.40

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Catherine Wood (Trades, Portfolio)'s ARK Investment has revealed additions to three biotechnology and telecommunications holdings according to GuruFocus' Real-Time Picks, a Premium feature.

Other stocks mentioned: CDXS, CMIIU, IRDM
2 weeks ago - GuruFocus

Brings 25 years of strategic leadership experience across healthcare Brings 25 years of strategic leadership experience across healthcare

3 weeks ago - GlobeNewsWire

Surface Oncology (NASDAQ: SURF) has announced new data from the ongoing Phase 1 studies of SRF388 and SRF617. SRF388 data will be presented at the American Society of Clinical Oncology 2021 Annual Meeting.

1 month ago - Benzinga

Surface Oncology (NASDAQ: SURF) has entered into a clinical trial collaboration with Roche Holdings AG (OTC: RHHBY) to evaluate former's SRF388, anti-IL-27 antibody, in combination with Roche's atezoliz...

Other stocks mentioned: RHHBY
1 month ago - Benzinga

Preliminary Data for SRF617 Show Good Tolerability and Promise in Combination Approaches

1 month ago - GlobeNewsWire

CAMBRIDGE, Mass., June 04, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenviro...

1 month ago - GlobeNewsWire

It's the right time to be decisive, if you can tolerate uncertainty.

2 months ago - The Motley Fool

Investors need to pay close attention to Surface Oncology (SURF) stock based on the movements in the options market lately.

2 months ago - Zacks Investment Research

Investors looking for a shot at big gains from this clinical-stage biotech will need to be comfortable with making a speculative buy.

2 months ago - The Motley Fool

CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenviron...

2 months ago - GlobeNewsWire

SRF388 Phase 1 Update to be Presented at American Society for Clinical Oncology Annual Meeting

3 months ago - GlobeNewsWire

Henry Rath announced as chief business officer, Alison O'Neill as chief medical officer and Jessica Fees as chief financial officer Henry Rath announced as chief business officer, Alison O'Neill as chie...

3 months ago - GlobeNewsWire

As of April 21, the GuruFocus All-in-One Screener, a Premium feature, found that the following guru-owned utilities have low price-earnings ratios. While some of them are great value investments, others...

Other stocks mentioned: BDSI, CODX, KMDA, VMD
3 months ago - GuruFocus

CAMBRIDGE, Mass., April 19, 2021 (GLOBE NEWSWIRE) -- Surface Oncology, a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today a...

3 months ago - GlobeNewsWire

CAMBRIDGE, Mass., April 09, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvir...

3 months ago - GlobeNewsWire

The company received an orphan drug designation from the FDA for one of its lead pipeline candidates.

3 months ago - The Motley Fool

Shares of Surface Oncology Inc. (NASDAQ: SURF), a clinical-stage biopharma company, gained more than 19% in the extended session on Tuesday. What Happened: The spike in shares came after the Cambridge, ...

3 months ago - Benzinga

Its pancreatic cancer drug gets a nod from the FDA.

3 months ago - The Motley Fool

CAMBRIDGE, Mass., March 30, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvir...

3 months ago - GlobeNewsWire

Every night, Cathie Wood's Ark Investment Management sends out an email listing the stocks that were bought or sold by the firm's ETFs that day. In recent months, the emails have been known to cause cer...

Other stocks mentioned: DDD, KMTUY, TSM
4 months ago - Benzinga

It's been a long time coming, but the great value comeback appears to be underway.

Other stocks mentioned: BIIB, DHI, HEAR, SENEA, OPY, SENEB
4 months ago - GuruFocus

CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvir...

4 months ago - GlobeNewsWire

AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC), Surface Oncology, Inc. (NASDAQ: SURF) and CorMedix Inc. (NASDAQ: CRMD) are among the biggest movers among health care stocks Tuesday.

Other stocks mentioned: ANPC, CRMD
4 months ago - Benzinga

Surface Oncology Inc (NASDAQ: SURF) has entered into a clinical trial collaboration with Merck & Co (NYSE: MRK) to evaluate Surface's SRF388 with the latter's Keytruda (pembrolizumab). This combination ...

4 months ago - Benzinga

Surface Oncology, Inc. (SURF) delivered earnings and revenue surprises of 345.71% and 3.02%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Surface Oncology (SURF) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock

4 months ago - Zacks Investment Research

New Collaboration with Merck Will Evaluate SRF388, Targeting IL-27, in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors

4 months ago - GlobeNewsWire

Surface Oncology (SURF) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

4 months ago - Zacks Investment Research

Surface Oncology, Inc. (SURF) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 months ago - Zacks Investment Research

CAMBRIDGE, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation therapies targeting the tumor microenvironment, t...

5 months ago - GlobeNewsWire

Experienced clinical development executive to succeed current CEO Jeff Goater, who will become Chairman of the Board

5 months ago - GlobeNewsWire

These baby biotechs are itching to come out of their shells.

Other stocks mentioned: JNCE
6 months ago - The Motley Fool

Investors need to pay close attention to Surface Oncology (SURF) stock based on the movements in the options market lately.

6 months ago - Zacks Investment Research

CAMBRIDGE, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenviro...

6 months ago - GlobeNewsWire

Surface Oncology, Inc. (SURF) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

7 months ago - Zacks Investment Research

Investors reacted negatively to a big licensing deal.

7 months ago - The Motley Fool

GSK will have exclusive rights to develop and commercialize SRF813, a novel antibody targeting PVRIG

7 months ago - GlobeNewsWire

Biotech investors had more than just vaccines to think about this year.

Other stocks mentioned: CRDF, FPRX, MRSN, TRIL
7 months ago - The Motley Fool

CAMBRIDGE, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenviro...

8 months ago - GlobeNewsWire

One has a better chance to keep climbing than the other does.

Other stocks mentioned: REPL
8 months ago - The Motley Fool

These three stocks are loaded with potential, but need to be watched carefully over the next few weeks.

Other stocks mentioned: BNTX, MRNA
8 months ago - The Motley Fool

Both programs have successfully escalated to dose levels demonstrating pharmacodynamic activity without dose - limiting toxicities

8 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenviro...

8 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenviro...

8 months ago - GlobeNewsWire

CAMBRIDGE, Mass, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenviron...

8 months ago - GlobeNewsWire

SRF388 inhibit s hepatocellular carcinoma tumor growth as a single agent in a preclinical model

8 months ago - GlobeNewsWire

Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

Other stocks mentioned: GRBK, HRI, MATX, MBIN
8 months ago - Zacks Investment Research

Crystal structure of IL-27 in complex with SRF388 demonstrates inhibition of downstream signaling events and provides basis to measure therapeutic inhibition of IL-27 Crystal structure of IL-27 in compl...

9 months ago - GlobeNewsWire

Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

Other stocks mentioned: CSTL, DQ, HRI
9 months ago - Zacks Investment Research

The small biotech could be preparing to sell to a big drugmaker.

9 months ago - The Motley Fool

About SURF

Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 (IgG4) monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; SRF813 targeting CD112R, an inhibitory protei... [Read more...]

Industry
Biotechnology
IPO Date
Apr 19, 2018
CEO
J. Jeffrey Goater
Employees
51
Stock Exchange
NASDAQ
Ticker Symbol
SURF
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for SURF stock is "Strong Buy." The 12-month stock price forecast is 16.40, which is an increase of 170.18% from the latest price.

Price Target
$16.40
(170.18% upside)
Analyst Consensus: Strong Buy